


PHARMACEUTICAL 2021



XENON

Xenon Pharmaceuticals Inc. Rank 74 of 409





PHARMACEUTICAL 2021





Xenon Pharmaceuticals Inc. Rank 74 of 409

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 115% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 424% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	181,783
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,781
Liabilities, Non-Current	3,050
Other Assets	3,849
Other Compr. Net Income	0
Other Expenses	227
Other Liabilities	0
Other Net Income	2,691
Property and Equipment	3,554
Research and Development	50,523
Revenues	32,166
Selling, General and Administrative Expense	12,944

Output Variable	Value in 1000 USD
Assets	189,186
Liabilities	17,831
Expenses	63,694
Stockholders Equity	171,355
Net Income	-28,837
Comprehensive Net Income	-28,837
Economic Capital Ratio	69%